4investors | Börsen-News | Adhoc- und Unternehmensnews | Medios

DGAP-News: Medios AG holds successful Annual General Meeting - Growth on track, forecast for financial year 2019 confirmed

Nachricht vom 10.07.2019 10.07.2019 (www.4investors.de - in Kooperation mit DGAP - EQS Group):

DGAP-News: Medios AG / Key word(s): AGM/EGM

Medios AG holds successful Annual General Meeting - Growth on track, forecast for financial year 2019 confirmed
10.07.2019 / 13:24

The issuer is solely responsible for the content of this announcement.
Medios AG holds successful Annual General Meeting - Growth on track, forecast for financial year 2019 confirmed
Berlin, 10 July 2019 - Medios AG ('Medios'), one the leading Specialty Pharma companies in Germany, has held its 2019 Annual General Meeting today. All agenda items were passed with a large majority. Altogether, around 64 per cent of the share capital was present. The agenda items included, among others, the discharge of the Management Board and Supervisory Board members, the election of the auditor as well as the creation of a new authorized and a new contingent capital 2019. In addition, the shareholders approved a profit-and-loss transfer agreement with Medios Analytics GmbH. The voting results for the agenda items can be found on the Medios AG website at https://medios.ag/en/investor-relations/general-assembly.
In the course of the Annual General Meeting, the Management Board of Medios AG presented its growth strategy and confirmed its forecast for the 2019 financial year. Accordingly, it is still anticipating group sales of EUR 430 to 440 million, earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for extraordinary expenses*, of EUR 16.5 to 17.5 million, and earnings before taxes (EBT), adjusted for extraordinary expenses*, of EUR 14.5 to 15.5 million. This represents sales growth of 31 to 34 per cent as well as a further increase in adjusted operating earnings*.Matthias Gärtner, CFO of Medios AG: 'We would like to sincerely thank our shareholders for the trust they have placed in us. We remain very confident that we will continue the Medios Group's dynamic growth course in the current financial year and increase our profitability once again.'

* EBITDA and EBT are both adjusted for extraordinary expenses for stock options in the amount of EUR 1.1 million (non-cash). EBT is additionally adjusted for extraordinary expenses of EUR 0.6 million (non-cash) for amortization on the customer base following the acquisition of operating units of BerlinApotheke Schneider & Oleski oHG.About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As a specialist for the provision of Specialty Pharma drugs to patients and GMP-certified provider of patient-specific therapies, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Usually, Specialty Pharma drugs are high-priced medicines for rare and/or chronic diseases. Patient-specific therapies are, for example, infusions that are compiled and produced on the basis of individual diseases and parameters like body weight and surface. It is Medios' aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.
Medios AG is Germany's first publicly listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard).Contact
Kirchhoff Consult AG
Nikolaus Hammerschmidt
Borselstraße 20
22765 Hamburg
Tel.: +49 40 60918618
Fax: +49 40 60918660
E-mail: nikolaus.hammerschmidt@kirchhoff.de
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.

10.07.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Medios AG

Friedrichstraße 113a

10117 Berlin

+49 30 232 566 - 800
+49 30 232 566 - 801
Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Dusseldorf
EQS News ID:

End of News
DGAP News Service

839335  10.07.2019 

Weitere DGAP-News von Medios

16.07.2019 - DGAP-News: Medios AG gewinnt österreichisches Family Office als Investor
10.07.2019 - DGAP-News: Medios AG hält erfolgreiche Hauptversammlung ab - Wachstumskurs intakt, Prognose für Geschäftsjahr 2019 bekräftigt
23.04.2019 - DGAP-Adhoc: Medios AG wächst im ersten Quartal stärker als erwartet und erhöht die Prognosen für das Geschäftsjahr 2019
18.04.2019 - DGAP-News: Medios AG: Veröffentlichung nach § 109 Absatz 2 Satz 1 WpHG
18.04.2019 - DGAP-News: Medios AG veröffentlicht Geschäftsbericht 2018

4investors-News zu Medios

16.07.2019 - Medios: Investor aus Österreich steigt ein
23.04.2019 - Medios erhöht Prognose für 2019
18.04.2019 - Medios: Neue Zahlen und ein fehlerhafter Abschluss
26.02.2019 - Medios: Aktienplatzierung erhöht Streubesitz
19.11.2018 - Medios: Keine Aktienplatzierung - zumindest vorerst


All Right Reserved by minimalthemes - ©2018 Stoffels & Barck GbR